$680M deal with CBC and Mubadala shifts UCB's strategy
Aug 29, 2024 · The $680 million transaction, announced on August 26, involves the sale of established brands such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along with UCB's Zhuhai manufacturing site, to CBC Group and Mubadala Investment Company.
Pharmaceutical Supply, Pharmaceutical Manufacturing, Contract …
Overcoming nonspecific binding challenges in pharmacokinetic assays The decentralized clinical trials market will grow to $25 billion by 2032 Aldevron’s Anu Codaty on passion, leadership, and innovation Women in Science: Sharmeen Roy - 'pharmacy is the perfect blend of all my favourite subjects' Women in STEM: Gitte Barknowitz’s journey to leading global initiatives Jane Koo on …
About us
About OutsourcingPharma. OutsourcingPharma is a comprehensive resource for the pharma industry with particular focus on small molecules, contract research organisations, patient centricity and data management with AI.
Manufacturing Drugs with Highly Potent APIs
Sep 28, 2023 · In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs), including: a review of the relevant guidance HPAPI classification systems safety processes to minimize exposure risk equipment and methods to prevent cross-contamination how to ensure GMP compliance for regulatory submissions DOWNLOAD THE ...
Premier Research: holistic approach benefits development
Oct 6, 2020 · Professionals focused on drug development are charged with making the most of their resources, maximizing the value of their work, and bringing effective products to market as quickly as they can without compromising quality or safety.
Enhance your cGMP chemical supply chain
Feb 9, 2023 · Supply chain issues have real, quantifiable impacts on biomanufacturers. However, the right support can make a cGMP supply chain operate seamlessly. Thermo Scientific™ Production Chemicals and Services can help streamline your total cost of ownership (TCO) so you can focus on producing safe, quality therapies and vaccines faster.
Specialized CRO ‘fills the gap’ for rare disease research
Feb 28, 2022 · Orphan Reach (a contract research organization that focuses on rare disease research) was acquired by CRO Emmes last year. Thomas Ogorka, managing director at Orphan Reach, spoke with Outsourcing-Pharma about the rare disease center’s work, as well as the current state and future of rare disease drug development.
Parexel to acquire functional service provider ExecuPharm
Sep 26, 2016 · King of Prussia, PA-based ExecuPharm provides clients with professionals in several areas, such as clinical monitoring or study management. The company also provides support with operational activities, including onboarding, training, line management, performance management, and policy administration.
Clinical trials & development
Senhwa Biosciences starts trial of silmitasertib in children with difficult to treat cancers. 07-Nov-2024 By Helen Albert . The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.
APIs - outsourcing-pharma.com
The small molecule drug arimoclomol (Miplyffa) has got the green light from the U.S. Food and Drug Administration (FDA) for the treatment of the rare disease Niemann-Pick disease type C (NPC), which until now has lacked FDA-approved therapies.